China NMPA approves Keymed Biosciences’ Stapokibart for atopic dermatitis

This approval is based on results from a multicentre, randomised, double-blind, placebo-controlled Phase III trial. The study’s co-primary endpoints were achieving a minimum of a 75% improvement in